Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment  

作　　者：Yun Chang Mingyang Chang Xiaoping Bao Cheng Dong 

机构地区：[1]Department of Biomedical Engineering,The Hong Kong Polytechnic University,999077,Hong Kong,China [2]The Hong Kong Polytechnic University Shenzhen Research Institute,Shenzhen,518000,China [3]Davidson School of Chemical Engineering,Purdue University,West Lafayette,IN,47907,USA [4]Purdue University Institute for Cancer Research,West Lafayette,IN,47907,USA

出　　处：《Bioactive Materials》2024年第12期379-403,共25页生物活性材料（英文）

基　　金：supported by start-up package funding from The Hong Kong Polytechnic University(Y.C.).

摘　　要：Adoptive immunotherapy,notably involving chimeric antigen receptor(CAR)-T cells,has obtained Food and Drug Administration(FDA)approval as a treatment for various hematological malignancies,demonstrating promising preclinical efficacy against cancers.However,the intricate and resource-intensive autologous cell processing,encompassing collection,expansion,engineering,isolation,and administration,hamper the efficacy of this therapeutic modality.Furthermore,conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers,the potential for cytokine release syndrome,and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment.Consequently,a strategic integration of adoptive immunotherapy with synergistic multimodal treatments,such as chemotherapy,radiotherapy,and vaccine therapy etc.,emerges as a pivotal approach to surmount these inherent challenges.This collaborative strategy holds the key to addressing the limitations delineated above,thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy.Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability,thereby advancing the frontiers of therapeutic precision and effectiveness.

关 键 词：Adoptive cellular immunotherapy Immune cell engineering Multiple-model synergistic therapy Tumor microenvironment 

分 类 号：R730.51[医药卫生—肿瘤]